CTIC

CTI BioPharma Corp. (CTIC) | Rumor.io

CTI BioPharma

CTIC

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CTIC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 22

CTI BioPharma Corp.'s stock price is seen as having a negative short-term outlook with a pessimistic long-term perspective.
Sofinnova increased its stake in CTI BioPharma Corp. to 17ml after making a profit on the company's stock.
There may be similarities between CTI BioPharma Corp. and GERN, with one user suggesting it could be a profitable investment opportunity.

Generated by AI

Sentiment

Of the messages about CTIC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	57.89% -39.76
Bearish	—	—	—	42.11% +39.76

Bullish· May 10

CTI BioPharma Corp. ($CTIC) is being acquired by Sobi in a $1.7B deal, representing a 90% premium.
The acquisition of CTI BioPharma by Sobi is expected to unlock significant value for the company, with potential for peak revenues of $500m-1B.
The buyout of CTI BioPharma is seen as a positive development for the biotech sector, with potential for other companies to follow a similar path.

Bearish· May 10

The acquisition of CTI BioPharma Corp. by a larger company may not be enough to recover the losses from previous offerings and reverse splits.
The stock's recent buyout was considered too low by some investors, and the company's phase 3 data may not be sustainable in the long term.
The imbalance of net option delta for CTI BioPharma Corp. is -939K, indicating negative pressure on the stock.

Generated by AI

Topics

Of the messages about CTIC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	98.5%
Controversies	—	—	—	0.5%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	1%

Analysts· Mar 2

$CTIC's price target was raised to $12 from $7.20 at Brookline, with a Buy rating, due to the FDA approval of Vonjo.
Analysts have a 85% buy consensus for $CTIC, with 12 analysts analyzed, indicating high confidence in the stock.
The average 12-month price target for $CTIC is $8.33, with a high forecast of $12.00 and a low forecast of $5.00, representing a 168.71% change from the last price.

Announcements· May 11

CTI BioPharma Corp. ($CTIC) is to be acquired by Swedish Orphan Biovitrum AB.
The acquisition is part of a trend of big pharma opening their wallets for acquisitions in the biotech industry.
The deal is similar to previous acquisitions of companies with drugs in similar fields, such as Merck-Imago and Gilead-Sierra.

Technical Analysis· Mar 4

CTI BioPharma Corp. (CTIC) has stalled horizontally due to a lack of sell volume and dried-up buy volume, potentially leading to a surge of volume and a push to $4.05.
The stock has a healthy trend, touching the upper end of the channel and bursting out, but may struggle at the daily resistance and potentially reject this price range.
CTIC is building for a big cup and handle on the 1-minute chart, with a potential break-out to $5.35 if shorts start covering or the price receives a boost from other factors.

Generated by AI

Community

Of the messages about CTIC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	92.35%
Newcomers	—	—	—	7.65%

Regulars· May 11

CTI BioPharma Corp. ($CTIC) has seen a trend towards late-stage acquisitions in the biotech sector, with big pharma companies opening their wallets for acquisitions.
The Stochastic Oscillator for $CTIC has left the oversold zone, indicating a potential change in market direction for the company.
CTI BioPharma Corp. ($CTIC) has been the subject of a potential sale, with some investors predicting a sale or acquisition, citing the company's complementary drug validated by the FDA.

Newcomers· May 10

The largest dark pool for CTIC today has a size of 2,550,757 shares, with a total value of $22,701,737.
CTI BioPharma Corp. (CTIC) has been acquired by Sobi in a deal valued at $1.7 billion, with a premium of 88% to the current price.
The acquisition is CTIC's 4th buyout for 2023, and the company's phase 3 data has forced a pivot in the market's bearish view, with one investor noting a 20-year perma bear stance.

Generated by AI

Also Discussed

Investors talking about CTIC also mention

#	Name	Attention
1	BeyondSpring Inc.BYSI	0%0
2	XOMA CorporationXOMA	0%0
3	Catalyst Pharmaceuticals Inc.CPRX	0%new
4	BDSI - BioDelivery Sciences International, Inc.	——
5	Cytokinetics, IncorporatedCYTK	0.01%+0
6	Camtek Ltd.CAMT	0%+0
7	Live Ventures IncorporatedLIVE	0%0
8	SPPI - Spectrum Pharmaceuticals, Inc.	——
9	FOLD - Amicus Therapeutics, Inc.	——
10	Incyte Corp.INCY	0%new

CTI BioPharma Corp.

Location

Social

What share of all stock conversation is about CTIC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 22

CTI BioPharma Corp.'s stock price is seen as having a negative short-term outlook with a pessimistic long-term perspective.
Sofinnova increased its stake in CTI BioPharma Corp. to 17ml after making a profit on the company's stock.
There may be similarities between CTI BioPharma Corp. and GERN, with one user suggesting it could be a profitable investment opportunity.

Generated by AI

Sentiment

Of the messages about CTIC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	57.89% -39.76
Bearish	—	—	—	42.11% +39.76

Bullish· May 10

CTI BioPharma Corp. ($CTIC) is being acquired by Sobi in a $1.7B deal, representing a 90% premium.
The acquisition of CTI BioPharma by Sobi is expected to unlock significant value for the company, with potential for peak revenues of $500m-1B.
The buyout of CTI BioPharma is seen as a positive development for the biotech sector, with potential for other companies to follow a similar path.

Bearish· May 10

The acquisition of CTI BioPharma Corp. by a larger company may not be enough to recover the losses from previous offerings and reverse splits.
The stock's recent buyout was considered too low by some investors, and the company's phase 3 data may not be sustainable in the long term.
The imbalance of net option delta for CTI BioPharma Corp. is -939K, indicating negative pressure on the stock.

Generated by AI

Topics

Of the messages about CTIC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	98.5%
Controversies	—	—	—	0.5%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	1%

Analysts· Mar 2

$CTIC's price target was raised to $12 from $7.20 at Brookline, with a Buy rating, due to the FDA approval of Vonjo.
Analysts have a 85% buy consensus for $CTIC, with 12 analysts analyzed, indicating high confidence in the stock.
The average 12-month price target for $CTIC is $8.33, with a high forecast of $12.00 and a low forecast of $5.00, representing a 168.71% change from the last price.

Announcements· May 11

CTI BioPharma Corp. ($CTIC) is to be acquired by Swedish Orphan Biovitrum AB.
The acquisition is part of a trend of big pharma opening their wallets for acquisitions in the biotech industry.
The deal is similar to previous acquisitions of companies with drugs in similar fields, such as Merck-Imago and Gilead-Sierra.

Technical Analysis· Mar 4

CTI BioPharma Corp. (CTIC) has stalled horizontally due to a lack of sell volume and dried-up buy volume, potentially leading to a surge of volume and a push to $4.05.
The stock has a healthy trend, touching the upper end of the channel and bursting out, but may struggle at the daily resistance and potentially reject this price range.
CTIC is building for a big cup and handle on the 1-minute chart, with a potential break-out to $5.35 if shorts start covering or the price receives a boost from other factors.

Generated by AI

Community

Of the messages about CTIC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	92.35%
Newcomers	—	—	—	7.65%

Regulars· May 11

CTI BioPharma Corp. ($CTIC) has seen a trend towards late-stage acquisitions in the biotech sector, with big pharma companies opening their wallets for acquisitions.
The Stochastic Oscillator for $CTIC has left the oversold zone, indicating a potential change in market direction for the company.
CTI BioPharma Corp. ($CTIC) has been the subject of a potential sale, with some investors predicting a sale or acquisition, citing the company's complementary drug validated by the FDA.

Newcomers· May 10

The largest dark pool for CTIC today has a size of 2,550,757 shares, with a total value of $22,701,737.
CTI BioPharma Corp. (CTIC) has been acquired by Sobi in a deal valued at $1.7 billion, with a premium of 88% to the current price.
The acquisition is CTIC's 4th buyout for 2023, and the company's phase 3 data has forced a pivot in the market's bearish view, with one investor noting a 20-year perma bear stance.

Generated by AI

CTI BioPharma

Social

May 22

Sentiment

Bullish· May 10

Bearish· May 10

Topics

Analysts· Mar 2

Announcements· May 11

Technical Analysis· Mar 4

Community

Regulars· May 11

Newcomers· May 10

Also Discussed

CTI BioPharma Corp.

Company Information

Location

Social

May 22

Sentiment

Bullish· May 10

Bearish· May 10

Topics

Analysts· Mar 2

Announcements· May 11

Technical Analysis· Mar 4

Community

Regulars· May 11

Newcomers· May 10

Also Discussed